Applied BioMath, LLC Launches Software Product for the Early Feasibility Assessment of Biotherapeutics Applied BioMath announces the release of Applied BioMath Assess™, an interactive, web-based application that helps project leaders, protein engineers and chemists, and modelers assess the difficulties and risks in developing a biotherapeutic. News provided by Share this article Share this article CONCORD, Mass., April 6, 2021 /PRNewswire/ -- Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, announced today the launch of Applied BioMath Assess™, an early feasibility assessment tool for biotherapeutics. Applied BioMath Assess is an interactive, web-based application that helps project leaders, protein engineers and chemists, and modelers assess the difficulties and risks in developing a biotherapeutic very early-on in a project. "Applied BioMath Assess was an essential step for our portfolio prioritization. We had several therapeutics under consideration and needed to understand what parameter ranges were required to achieve our desired outcomes," said David de Graaf, PhD, Co-Founder of Tuned Therapeutics. "Being able to quickly analyze each therapeutic helped us identify which therapeutics were best to pursue and ultimately helped us de-risk our portfolio and provide a clear and scientific rationale with our stakeholders."